Phase 12a study of TLK286 (a novel glutathione analog) in combination with carboplatin in platinum refractory or resistant ( 3rd line) ovarian cancer Journal of Clinical Oncology Frontiers Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment Carbon monoxide sensitizes cisplatin resistant ovarian cancer cell lines toward cisplatin via attenuation of levels of glutathione and nuclear metallothionein ScienceDirect Platinum resistance in epithelial ovarian cancer: an interplay of epithelialmesenchymal transition interlinked with reprogrammed metabolism Journal of Translational Medicine Springer Nature Link Drug resistance in ovarian cancer: from mechanism to clinical trial Molecular Cancer Springer Nature Link